Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track?

Santhera Pharmaceuticals reported a widened H1 net loss of CHF 38.83 million, largely due to a $25 million milestone payment, despite a 70% increase in contract revenue to CHF 24.01 million. The company raised its FY2025 revenue guidance above CHF 65-70 million, reiterated long-term targets, and projects achieving cash break-even by mid-2026, driven by strong global demand for its Duchenne muscular dystrophy drug AGAMREE, which saw sales exceed $100 million over four consecutive quarters and US partner Catalyst projecting $100-110 million for 2025. Shares, however, dropped 6.20% following the announcement.

Analysis

Santhera Pharmaceuticals' first-half results present a clear divergence between headline accounting figures and underlying operational momentum. The company reported a widened net loss of 38.83 million francs, a significant increase from 15.26 million francs year-over-year, which prompted a 6.20% drop in its share price. However, this loss was primarily driven by a one-time $25 million milestone payment related to its key drug, AGAMREE, rather than a deterioration in core business performance. Operationally, the company demonstrated robust growth, with revenue from contracts rising 70% to 24.01 million francs and net sales growing 76%, fueled by the successful 2024 launch of AGAMREE in Germany and Austria. The global commercial traction for AGAMREE is further evidenced by four-quarter rolling sales exceeding $100 million and a strong 2025 sales projection of $100-$110 million from its US partner, Catalyst Pharmaceuticals. Consequently, Santhera has raised its fiscal 2025 revenue guidance above the previous 65-70 million franc range and reaffirmed its targets to achieve cash break-even by mid-2026 and generate 150 million euros in revenue by 2028. The market's negative reaction appears to be focused on the near-term cash burn and accounting loss, potentially overlooking the strong forward-looking indicators and commercial execution.

Key Decisions for Investors

• Investors should look past the headline net loss, which was distorted by a one-off milestone payment, and focus on the strong operational metrics, including the 70% growth in contract revenue and the upgraded FY2025 revenue guidance.
• The primary risk is execution; therefore, it is critical to monitor AGAMREE's sales trajectory in the coming quarters to validate the company's path to achieving its stated mid-2026 cash break-even target.
• Key catalysts that could lead to a re-rating of the stock include the presentation of real-world evidence data in October 2024 and the new long-term effectiveness data from the GUARDIAN study in Q4 2025, which could de-risk the long-term sales profile.